JPRN-C000000314
已完成
1 期
Phase I-II clinical trial of irinotecan hydrochloride (CPT-11) for refractory pediatric solid tumors - CPT-PED-05
CPT-PED-05 administrative office0 个研究点目标入组 30 人2006年1月27日
概览
- 阶段
- 1 期
- 干预措施
- 未指定
- 疾病 / 适应症
- 未指定
- 发起方
- CPT-PED-05 administrative office
- 入组人数
- 30
- 状态
- 已完成
- 最后更新
- 2年前
概览
简要总结
暂无简介。
研究者
入排标准
入选标准
- 未提供
排除标准
- •1\) a patient who received transfusion, blood products, or hematopoietic growth factors such as G\-CSF within 7 days prior to the registration 2\) a patient who has another active malignant disease, which is untreated or whose control period is less than 5years, in different site 3\) a patient with symptomatic metastasis to central nervous system, or a patient with primary central nervous system tumor 4\) a patient who is complicated with serious disease as below; 1\. infection, diarrhea, ileus, paralytic ileus 2\. malignant fluid retention (pleural effusion, ascites, pericardiac effusion) 3\. interstitial pneumonia or pulmonary fibrosis 4\. cardiac disease 5\. other disease which possibly interfere the trial 5\) a patient who is pregnant, during breast\-feeding, possibly pregnant, or willing to be pregnant 6\) past history of serious drug allergy 7\) past history of administration of CPT\-11 8\) a patient who was judged as inappropriate for the trial
结局指标
主要结局
未指定
相似试验
已完成
1 期
Phase I-II clinical trial of irinotecan hydrochloride (CPT-11) for refractory pediatric solid tumorsJPRN-jRCT1091220004CPT-PED-05 administrative office30
招募中
1 期
A Phase I/IIa trial of HA-Irinotecan, a formulation of hyaluronic acid and irinotecan, in the treatment of extensive stage small cell lung cancer and its effect on tumour stem cells.ACTRN12611000520932Southern Health40
招募中
2 期
Randomised Phase II trial of irinotecan with hyaluronic acid (HyCAMP) versus irinotecan as treatment for patients with metastatic colorectal cancer who have failed 5-FU based chemotherapyMetastatic colorectal cancerCancer - Bowel - Back passage (rectum) or large bowel (colon)ACTRN12605000119695Meditech Research Limited86
已完成
1 期
Utomilumab, Cetuximab, and Irinotecan Hydrochloride in Treating Patients With Metastatic Colorectal CancerNCT03290937M.D. Anderson Cancer Center34
尚未招募
不适用
rechallenge high-dose irinotecan with UGT1A1 genotype in metastatic colorectal cancerNeoplasmsKCT0005303ational Cancer Center37